LG Life Sciences Expands Diabetes Drug Market To 104 Countries
This article was originally published in PharmAsia News
Executive Summary
LG Life Sciences has reached an outlicensing deal with Mexico's Stendhal to market the Zemiglo (gemigliptin) and ZemiMet diabetes drugs in 23 Central and South America countries.